Vcreate develops T-cell receptor (TCR) based therapeutics using machine learning to engineer high-precision drugs against previously untreatable diseases. The company employs novel molecular biology and single-cell sequencing assays to achieve over 100x faster discovery of TCR-antigen interactions. This platform enables the design of TCRs capable of targeting intracellular disease-specific antigens with high specificity.
Funding
Funding not disclosed
Founders
Product
Problem
The discovery of effective T-cell receptors (TCRs) for targeted cancer therapies is a significant bottleneck, as traditional methods struggle to efficiently identify TCRs that bind to disease-specific antigens with high precision and specificity. Existing screening assays often lack the throughput and sensitivity needed to comprehensively explore the vast TCR-antigen interaction space.
Solution
Vcreate is developing a biotechnology platform that leverages machine learning and high-throughput screening assays to accelerate the discovery and engineering of human T-cell receptors (TCRs) for targeted cancer immunotherapies. Their platform enables the interrogation of millions of TCR-antigen interactions in a single experiment, significantly increasing the speed and efficiency of TCR identification. By combining novel molecular biology techniques with single-cell sequencing and machine learning algorithms, Vcreate can design TCR-based drugs that precisely target and destroy disease cells while sparing healthy tissue. The platform can also be used to identify TCRs that target rare cancer mutations, even when those mutations are not present in experimental datasets.
Target Audience
The primary target audience includes biotechnology and pharmaceutical companies focused on developing novel cancer immunotherapies, as well as research institutions and academic labs involved in TCR engineering and cancer research.
Features
- High-throughput screening assays capable of interrogating hundreds of millions of TCR-antigen interactions
- Machine learning algorithms for designing TCRs that activate against specific targets, including rare cancer mutations
- Single-cell sequencing to generate datasets for training machine learning models
- Ability to identify TCRs that can target intracellular targets undruggable by most therapies
- Platform designed to identify high-precision TCR-based drugs that selectively destroy target cells